QuidelOrtho Corporation (QDEL)
QDEL Stock Price Chart
Explore QuidelOrtho Corporation interactive price chart. Choose custom timeframes to analyze QDEL price movements and trends.
QDEL Company Profile
Discover essential business fundamentals and corporate details for QuidelOrtho Corporation (QDEL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Instruments & Supplies
IPO Date
1 Feb 1991
Employees
6.60k
Website
https://www.quidelortho.comCEO
Brian J. Blaser
Description
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
QDEL Financial Timeline
Browse a chronological timeline of QuidelOrtho Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Jul 2026
EPS estimate is -$0.04, while revenue estimate is $619.54m.
Earnings released on 5 May 2026
EPS came in at -$0.04 falling short of the estimated $0.37 by -110.81%, while revenue for the quarter reached $619.80m , missing expectations by -6.83%.
Earnings released on 11 Feb 2026
EPS came in at $0.46 surpassing the estimated $0.43 by +6.98%, while revenue for the quarter reached $723.60m , beating expectations by +3.26%.
Earnings released on 5 Nov 2025
EPS came in at $0.80 surpassing the estimated $0.51 by +56.86%, while revenue for the quarter reached $699.90m , beating expectations by +4.57%.
Earnings released on 5 Aug 2025
EPS came in at $0.12 surpassing the estimated $0.00 by +7.74k%, while revenue for the quarter reached $613.90m , beating expectations by +0.45%.
Earnings released on 7 May 2025
EPS came in at $0.74 surpassing the estimated $0.58 by +27.59%, while revenue for the quarter reached $692.80m , beating expectations by +0.46%.
Earnings released on 12 Feb 2025
EPS came in at $0.63 surpassing the estimated $0.59 by +6.60%, while revenue for the quarter reached $707.80m , beating expectations by +1.24%.
Earnings released on 7 Nov 2024
EPS came in at $0.85 surpassing the estimated $0.31 by +174.19%, while revenue for the quarter reached $727.10m , beating expectations by +13.23%.
Earnings released on 31 Jul 2024
EPS came in at -$0.07 surpassing the estimated -$0.21 by +66.67%, while revenue for the quarter reached $637.00m , beating expectations by +3.83%.
Earnings released on 8 May 2024
EPS came in at $0.44 surpassing the estimated $0.43 by +2.33%, while revenue for the quarter reached $711.00m , beating expectations by +2.56%.
Earnings released on 13 Feb 2024
EPS came in at $1.17 falling short of the estimated $2.02 by -42.08%, while revenue for the quarter reached $742.60m , missing expectations by -6.81%.
Earnings released on 1 Nov 2023
EPS came in at $0.90 surpassing the estimated $0.60 by +50.50%, while revenue for the quarter reached $744.00m , beating expectations by +7.53%.
Earnings released on 8 Aug 2023
EPS came in at $0.26 surpassing the estimated $0.25 by +4.00%, while revenue for the quarter reached $665.10m , beating expectations by +8.13%.
Earnings released on 3 May 2023
EPS came in at $1.80 surpassing the estimated $1.40 by +28.57%, while revenue for the quarter reached $846.10m , beating expectations by +8.75%.
Earnings released on 15 Feb 2023
EPS came in at $1.76 surpassing the estimated $1.40 by +25.71%, while revenue for the quarter reached $866.50m , beating expectations by +12.45%.
Earnings released on 2 Nov 2022
EPS came in at $1.85 surpassing the estimated $0.74 by +149.66%, while revenue for the quarter reached $783.80m , beating expectations by +8.92%.
Earnings released on 4 Aug 2022
EPS came in at $2.12 falling short of the estimated $2.68 by -20.90%, while revenue for the quarter reached $613.40m , missing expectations by -20.15%.
Earnings released on 4 May 2022
EPS came in at $11.66 surpassing the estimated $9.89 by +17.90%, while revenue for the quarter reached $1.00bn , beating expectations by +12.48%.
Earnings released on 17 Feb 2022
EPS came in at $7.29 surpassing the estimated $4.89 by +49.08%, while revenue for the quarter reached $636.87m , beating expectations by +17.74%.
Earnings released on 4 Nov 2021
EPS came in at $5.36 surpassing the estimated $0.87 by +516.09%, while revenue for the quarter reached $509.80m , beating expectations by +188.10%.
Earnings released on 5 Aug 2021
EPS came in at $0.75 falling short of the estimated $1.20 by -37.50%, while revenue for the quarter reached $176.60m , missing expectations by -0.01%.
QDEL Stock Performance
Access detailed QDEL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
